| 炎症及NLRP3炎性小体在肺动脉高压中的作用研究进展 |
| |
| 引用本文： | 周声志,陈建英. 炎症及NLRP3炎性小体在肺动脉高压中的作用研究进展[J]. 实用心脑肺血管病杂志, 2020, 0(5): 116-120 |
| |
| 作者姓名： | 周声志 陈建英 |
| |
| 作者单位： | 广东医科大学附属医院心血管内科 |
| |
| 基金项目： | 国家自然科学基金面上项目(81370242);广东医科大学附属医院干细胞临床前研究项目(2018PSSC006)。 |
| |
| 摘 要： | 肺动脉高压是以肺动脉压力进行性升高为主要特征的肺血管疾病,可导致右心衰竭甚至死亡,目前尚无特效药。近年医学界发现炎症参与了肺动脉高压的发生、发展,其中NLRP3炎性小体作为启动固有免疫应答的关键炎症信号平台有望成为人们系统性认识肺动脉高压炎症性质的蛋白复合物,也可能是治疗的潜在靶点。本文就炎症及NLRP3炎性小体在肺动脉高压中的作用进行综述。
|
| 关 键 词： | 肺动脉高压 炎症 NLRP3 炎性小体 |
Research Progress of the Role of Inflammation and NLRP3 Inflammasome in Pulmonary Hypertension |
| |
| ZHOU Shengzhi,CHEN Jianying. Research Progress of the Role of Inflammation and NLRP3 Inflammasome in Pulmonary Hypertension[J]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease, 2020, 0(5): 116-120 |
| |
| Authors: | ZHOU Shengzhi CHEN Jianying |
| |
| Affiliation: | (Department of Cardiovascular,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524011,China) |
| |
| Abstract: | Pulmonary hypertension is a pulmonary vascular disease that characterized by the progressive increase of pulmonary artery pressure,it can cause right heart failure and even death,but there are still no effective drugs.In recent years,the academic community has found that inflammation is involved in many pathogenesis of pulmonary hypertension,the NLRP3 inflammasome,as a key inflammatory signal platform that initiates innate immune response,regulates the level of inflammation is expected to be a protein complex that systematically recognizes the inflammatory properties of pulmonary hypertension and may also be a potential target for treatment. |
| |
| Keywords: | Pulmonary hypertension Inflammation NLRP3 Inflammasome |
| 本文献已被 CNKI 维普 等数据库收录！ |
